Brief: ORIC Pharmaceuticals Announces Regulatory Clearance Of Clinical Trial Application
25/01/2022 14:15
Jan 25 (Reuters) - Oric Pharmaceuticals Inc ORIC.O :
* ORIC PHARMACEUTICALS ANNOUNCES REGULATORY CLEARANCE OF
CLINICAL
TRIAL APPLICATION FOR ORIC-114 IN ADVANCED SOLID TUMORS WITH
EGFR OR HER2 EXON 20 ALTERATIONS OR HER2 AMPLIFICATIONS
Source text for Eikon: ID:nGNX5gt4jm
Further company coverage: ORIC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ORIC Pharmaceuticals
See all newsBrief: Oric® Pharmaceuticals Announces Agreement With Cancer Research UK
ORIC Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: ORIC Pharmaceuticals Q1 Operating Expenses USD 39.619 Million
Brief: Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ORIC Pharmaceuticals Q4 loss narrows